Identification and characterization of a murine receptor for galactose-terminated glycoproteins
โ Scribed by Wanjin Hong; Anh Van Le; Darrell Doyle
- Publisher
- John Wiley and Sons
- Year
- 1988
- Tongue
- English
- Weight
- 687 KB
- Volume
- 8
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
โฆ Synopsis
The asialoglycoprotein receptor, the hepatic binding lectin for galactose-terminated glycoproteins, has been isolated and characterized from human, rabbit and rat liver. Several recent studies have shown the existence of the same receptor in murine liver. However, the biochemical structure of the receptor in murine liver has not been resolved. In this paper, we describe the identification and purification of the receptor for asialoglycoproteins from murine liver. The purified receptor has three polypeptides with apparent molecular weights of 42,000, 45,000 and 51,000, respectively, as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Furthermore, our studies suggest that the receptor from murine liver is very similar to its counterpart in rat liver, although some potential interesting differences have also been observed. Initial studies indicate that this receptor is well conserved in different mouse strains.
๐ SIMILAR VOLUMES
## Abstract Early investigators reported the occurrence of unidentified protein factors in biological fluids that may regulate sperm motility essential for fertility potential. This study reports for the first time purification of a forward motility stimulating protein (FMSFโI), to apparent homogen
Vitamin D receptor (VDR) and its ligands play important roles in mineral/skeletal homeostasis, cell proliferation/differentiation, and modulation of immune responses. VDR ligands make attractive candidates for the treatment/prevention of osteoporosis, psoriasis, and cancer. The major issue with cur
We have identified a preparation of recombinant murine interleukin-6 (mIL-6) that, in addition to the anticipated product, also contained approximately equal amounts of mIL-6 with a C-terminal pentapeptide extension. The extension mutant was generated by readthrough of the stopcodon, and termination
Clinicians now have an extensive and effective pharmacopeia to treat the symptoms of Parkinson's disease - especially in the early and moderate stages of the disorder. Ultimately, a significant number of patients with the disorder find that, as their disease progresses, pharmacotherapy fails to cont